Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.58 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.50 |
| ▸ | LCK | P06239 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RGS12 | O14924 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388077 | 1.00 | SYK (0.58) | SYKKDM4CPPARASTING1CA1 | |
| SCHEMBL28928409 | 0.93 | PPARA (0.52) | SYKKDM4CPPARASTING1CA1 | |
| SCHEMBL608754 | 0.87 | NOX4 (0.61) | SYKKDM4CPPARASTING1MAPT | |
| SCHEMBL610065 | 0.86 | KDM4C (0.53) | SYKKDM4CPPARASTING1MAPT | |
| SCHEMBL29391568 | 0.86 | KDM4C (0.53) | SYKKDM4CPPARASTING1MAPT | |
| SCHEMBL4095004 | 0.86 | KDM4C (0.56) | SYKKDM4CPPARASTING1MAPT | |
| SCHEMBL29388557 | 0.86 | KDM4C (0.74) | SYKKDM4CPPARASTING1CA1 | |
| SCHEMBL607997 | 0.86 | KDM4C (0.74) | SYKKDM4CPPARASTING1CA1 | |
| SCHEMBL29391594 | 0.85 | PPARA (0.57) | SYKKDM4CPPARASTING1MAPT | |
| SCHEMBL610930 | 0.85 | PPARA (0.57) | SYKKDM4CPPARASTING1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3902536-B1 | COMPOSITIONS COMPRISING 5-BENZYLAMINOSALICYLIC ACID COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS IN A COMPANION ANIMAL | GNT PHARMA CO LTD (KR) | 2025-09-03 | — | — | EP | claimed |
| WO-2023156808-A2 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2023-08-24 | — | — | WO | claimed |
| US-20230233503-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2023-07-27 | — | — | US | claimed |
| US-20220249343-A1 | COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF | GNT PHARMA CO., LTD. (KR) | 2022-08-11 | — | — | US | claimed |
| US-20220241231-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2022-08-04 | — | — | US | claimed |
| EP-3998058-A1 | COSMETIC COMPOSITION COMPRISING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND LOCAL ADMINISTRATION METHOD THEREOF | GNT Pharma Co., Ltd (KR) | 2022-05-18 | — | — | EP | claimed |
| CN-114096227-A | Cosmetic compositions comprising 5-benzylaminosalicylic acid derivatives and methods of topical use thereof | 吉恩特药业株式会社 | 2022-02-25 | — | — | CN | claimed |
| CN-113710242-A | Compositions and methods for treating neurodegenerative disorders | 吉恩特药业株式会社 | 2021-11-26 | — | — | CN | claimed |
| EP-3902536-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT Pharma Co., Ltd (KR) | 2021-11-03 | — | — | EP | claimed |
| WO-2021006637-A1 | COSMETIC COMPOSITION COMPRISING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND LOCAL ADMINISTRATION METHOD THEREOF | 주식회사 지엔티파마 | 2021-01-14 | — | — | WO | claimed |
| WO-2020136441-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2020-07-02 | — | — | WO | claimed |
| US-20200206172-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2020-07-02 | — | — | US | claimed |
| US-20130316988-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2013-11-28 | — | — | US | claimed |
| US-8455470-B2 | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH PHARMACEUTICALS CO., LTD (KR) | 2013-06-04 | — | — | US | claimed |
| US-20120040939-A1 | MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-02-16 | — | — | US | claimed |
| CN-102316863-A | The medical usage of 5-benzylamino salicyclic acid derivatives or its salt | NEUROTECH PHARMACEUTICALS CO L | 2012-01-11 | — | — | CN | claimed |
| US-20090281181-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | GNT PHARMA CO., LTD. (KR) | 2009-11-12 | — | — | US | claimed |
| EP-2004164-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES | Neurotech Co., Ltd. (KR) | 2008-12-24 | — | — | EP | claimed |
| WO-2007119973-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES | NEUROTECH CO., LTD. (KR) | 2007-10-25 | — | — | WO | claimed |
| EP-3902536-B1 | COMPOSITIONS COMPRISING 5-BENZYLAMINOSALICYLIC ACID COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS IN A COMPANION ANIMAL | GNT PHARMA CO LTD (KR) | 2025-09-03 | — | — | EP | disclosed |
| US-20250255844-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2025-08-14 | — | — | US | disclosed |
| US-12285402-B2 | Compositions and methods for treating pulmonary disorders | GNT PHARMA CO., LTD. (KR) | 2025-04-29 | — | — | US | disclosed |
| CN-114096227-B | Cosmetic compositions comprising 5-benzylaminosalicylic acid derivatives and methods of topical use thereof | 吉恩特药业株式会社 | 2023-11-07 | — | — | CN | disclosed |
| WO-2023156808-A2 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| US-20230233503-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | GNT PHARMA CO., LTD. (KR) | 2023-07-27 | — | — | US | disclosed |
| US-20220249343-A1 | COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF | GNT PHARMA CO., LTD. (KR) | 2022-08-11 | — | — | US | disclosed |
| US-20220241231-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2022-08-04 | — | — | US | disclosed |
| EP-3998058-A1 | COSMETIC COMPOSITION COMPRISING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND LOCAL ADMINISTRATION METHOD THEREOF | GNT Pharma Co., Ltd (KR) | 2022-05-18 | — | — | EP | disclosed |
| CN-114096227-A | Cosmetic compositions comprising 5-benzylaminosalicylic acid derivatives and methods of topical use thereof | 吉恩特药业株式会社 | 2022-02-25 | — | — | CN | disclosed |
| CN-113710242-A | Compositions and methods for treating neurodegenerative disorders | 吉恩特药业株式会社 | 2021-11-26 | — | — | CN | disclosed |
| EP-3902536-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT Pharma Co., Ltd (KR) | 2021-11-03 | — | — | EP | disclosed |
| WO-2021006637-A1 | COSMETIC COMPOSITION COMPRISING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE AND LOCAL ADMINISTRATION METHOD THEREOF | 주식회사 지엔티파마 | 2021-01-14 | — | — | WO | disclosed |
| WO-2020136441-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2020-07-02 | — | — | WO | disclosed |
| US-20200206172-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GNT PHARMA CO., LTD. (KR) | 2020-07-02 | — | — | US | disclosed |
| EP-2004164-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | NEUROTECH PHARMACEUTICALS CO LTD (KR) | 2018-08-08 | — | — | EP | disclosed |
| CN-103211824-B | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | 纽若泰克制药株式会社 | 2017-04-19 | — | — | CN | disclosed |
| EP-2394645-B1 | Medical use of 5-benzylamino salicylic acid derivatives or salts thereof | NEUROTECH PHARMACEUTICALS CO LTD (KR) | 2014-10-08 | — | — | EP | disclosed |
| US-8598383-B2 | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2013-12-03 | — | — | US | disclosed |
| US-20130316988-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2013-11-28 | — | — | US | disclosed |
| US-8455470-B2 | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH PHARMACEUTICALS CO., LTD (KR) | 2013-06-04 | — | — | US | disclosed |
| CN-101538218-B | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH CO LTD | 2013-05-29 | — | — | CN | disclosed |
| CN-101426484-B | Application of pharmaceutical composition in preparation of medicines for treating or preventing degenerative and inflammatory diseases | NEUROTECH CO LTD | 2013-05-22 | — | — | CN | disclosed |
| US-20120209025-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | GWAG BYOUNG-JOO (KR) | 2012-08-16 | — | — | US | disclosed |
| US-20120040939-A1 | MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-02-16 | — | — | US | disclosed |
| CN-102316863-A | The medical usage of 5-benzylamino salicyclic acid derivatives or its salt | NEUROTECH PHARMACEUTICALS CO L | 2012-01-11 | — | — | CN | disclosed |
| US-20090281181-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | GNT PHARMA CO., LTD. (KR) | 2009-11-12 | — | — | US | disclosed |
| US-20090240079-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2009-09-24 | — | — | US | disclosed |
| CN-101538218-A | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH CO LTD | 2009-09-23 | — | — | CN | disclosed |
| CN-101426484-A | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH CO LTD (KR) | 2009-05-06 | — | — | CN | disclosed |
| EP-2004164-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES | Neurotech Co., Ltd. (KR) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007119973-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES | NEUROTECH CO., LTD. (KR) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007119973-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES | NEUROTECH CO., LTD. (KR) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233503-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | HAO2, ACOX1, HAO1 | SYK 2333/4885KDM4C 3145/4885PPARA 813/4885 |
| US-20120209025-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | SYK 1765/4885KDM4C 4051/4885PPARA 223/4885 |
| US-20220241231-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | PRNP, PSEN1, GRIK5 | SYK 3071/4885KDM4C 2280/4885PPARA 3388/4885 |
| US-20250255844-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | HAO2, ACOX1, HAO1 | SYK 2333/4885KDM4C 3145/4885PPARA 813/4885 |
| US-12285402-B2 | Compositions and methods for treating pulmonary disorders | HAO2, ACOX1, HAO1 | SYK 2333/4885KDM4C 3145/4885PPARA 813/4885 |
| US-20090240079-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | SYK 1765/4885KDM4C 4051/4885PPARA 223/4885 |
| US-20120040939-A1 | MEDICINAL USE OF 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE OR ITS SALT | HTR5A, HTR6, MC5R | SYK 1284/4885KDM4C 2416/4885PPARA 1630/4885 |
| US-20090281181-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | SYK 1765/4885KDM4C 4051/4885PPARA 223/4885 |
| US-20130316988-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | SYK 1765/4885KDM4C 4051/4885PPARA 223/4885 |
| US-20220249343-A1 | COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOF | ALOX5, ALOX15, IL5 | SYK 2252/4885KDM4C 1095/4885PPARA 908/4885 |
| US-20200206172-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | PRNP, PSEN1, GRIK5 | SYK 3071/4885KDM4C 2280/4885PPARA 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.